- Recruiting participants (Starts Sep. 29, 2014)
- Not accepting healthy volunteers
- UTSW Principal Investigator: TIFFANY R SIMMS-WALDRIP
summary
This is not considered research. We are requesting iRB approval forfor use of CliniMaCS CD34 Reagent System to obtain CD34+ cell-enriched population for hematopoietic reconstitution following a myeloblative preparative regimen without the need for additonal graft versus host disease (GVHD) prophylaxis.
objective
To process hematopoietic progenitor cells collected by apheresis (HPC, apheresis) from an related or unrelated donor to obtain CD34 enriched population for hematopoietic reconstitution following a myeloblative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis.
eligibility
Not applicable as this is not a research study,